Ghent, Porto, Wroclaw: Future European HealthTech and MedTech Hubs

Nelson Advisors
10 hours ago
13 min read

The European medical technology and healthcare innovation landscape is currently traversing a period of profound structural realignment, characterised by a transition from speculative digital fragmentation toward a model of industrial maturity and regulatory rigor.

As the global MedTech market is projected to expand from a valuation of $549.5 Billion in 2025 to approximately $853.4 Billion by 2035, growing at a compound annual growth rate (CAGR) of 4.5%, the European theatre is emerging as a critical frontier for high-conviction investment and clinical validation. This transformation is driven by a convergence of high medical trend rates, which are expected to reach 11.68% globally in 2025, and a persistent workforce crisis that has seen burnout rates among medical staff climb to 63% in regions like Spain and 36% in France.

Consequently, three specific European hubs, Ghent in Belgium, Porto in Portugal, and Wroclaw in Poland are manifesting as primary centres of excellence, leveraging unique combinations of institutional heritage, sovereign funding and technological specialisations in robotics, genomic data and artificial intelligence (AI).

The broader European life sciences sector entered 2026 with renewed optimism, supported by a significant rebound in venture capital (VC) investment. In the first half of 2025, global MedTech funding reached $15.4 Billion, a 13% increase from the previous year, signalling a stabilisation of investor appetite after a period of correction. Within Europe, healthcare and life sciences VC volumes reached €13.22 Billion in 2025, representing a 2.8% year-on-year increase. This capital deployment is increasingly governed by "industrial logic," wherein value is derived from operational leverage and clinical utility rather than theoretical scalability. Investors are prioritising "high-conviction bets" on companies with validated clinical data and clear pathways to reimbursement, particularly in the digital health sector, which rebounded to $7.9 Billion globally in H1 2025.

The market is bifurcating between established giants and emerging specialized clusters. While the United States continues to dominate nearly 80% of global MedTech venture capital, Europe’s 15–20% share is becoming more concentrated in hubs that can navigate the "Regulatory Darwinism" imposed by the EU Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR). These regulations, while administratively burdensome, are creating a "compliance moat" for firms capable of securing certification, effectively transforming regulatory status into a primary valuation driver.

Macro-Economic Determinants and the Regulatory Landscape

The implementation of the EU MDR and IVDR frameworks has fundamentally altered the competitive dynamics of the European HealthTech sector. As of 2025, the certification process remains a significant bottleneck, with over 28,000 MDR applications filed but only 12,000 certificates issued; approximately 60% of cases require 13 to 18 months for completion.

This environment favors hubs with robust institutional support and dedicated regulatory consulting infrastructure. From May 28, 2026, the mandatory adoption of the European Databank on Medical Devices (EUDAMED) modules, specifically for Actor Registration and Notified Body Certificates, will further formalize transparency. This regulatory convergence acts as a filter, distinguishing "investable assets" from "distressed liabilities" based on their ability to meet stringent data governance and human oversight standards required by the EU AI Act. Companies that successfully operationalise these requirements are finding they can command higher valuation multiples, as they are viewed as lower-risk entries for large-scale acquisitions by pharmaceutical and MedTech incumbents seeking to fill their innovation pipelines.

The financial health of the sector is also influenced by the "Dry Powder Paradox." While private equity and venture capital funds hold nearly $2.5 Trillion in unallocated capital, deployment is highly selective, favouring platforms that demonstrate industrial logic over theoretical potential. The investment logic has shifted from "venture subsidies" to "industrial logic," where value is created through operational leverage, vertical integration, and the arbitrage of fragmented markets.

European MedTech and Digital Health Market Forecasts (2025–2030)

Sector / Region	Value (2025 Projected)	Value (2030 Projected)	CAGR (%)
Global MedTech Market	$549.5 Billion	$685.2 Billion	4.5%
European MedTech Market	£125.4 Billion	£155.2 Billion	4.4%
UK MedTech Market	£15.7 Billion	£20.5 Billion	5.4%
European Digital Health	—	—	22.3%
European Digital MSK	$1.22 Billion	$3.28 Billion	18.1%

Hub 1: Tech Lane Ghent > The Benelux Axis of BioTechnical Integration

Ghent, Belgium, has solidified its position as a premier European Life Sciences hub, primarily through the concentrated development of Tech Lane Ghent Science Park. This 52-hectare ecosystem hosts over 60 research-oriented companies and is the focal point for 79% of all VC funding in Belgium as of 2025. The hub’s strategy relies on the seamless integration of academic research from Ghent University (UGent) and the Flemish Institute of Biotechnology (VIB) with commercial scaling capabilities.

Infrastructure Pipeline and Expansion (2026–2029)

The growth trajectory of Tech Lane Ghent is supported by a massive infrastructure pipeline designed to accommodate the transition from early-stage research to industrial manufacturing. The Science Park is divided into two main zones, Zwijnaarde and Ardoyen, which collectively host a range of specialised facilities including the VIB Bio-Incubator and the Obelisc Bio-Accelerator.

Project Name	Location	Estimated Completion	Facility Type / Scale
Nobel I Building (UZ Gent)	Ghent South	2026	18,000 sq m Lab & Office
Kadans & PMV Life Sciences Hub	Tech Lane	2026 (Phased)	20,000 sq m Lab & Office
Plus Ultra Gent	Tech Lane	2027	20,000 sq m Multi-tenant
AI Campus Hub - The Brain	Campus Ardoyen	2027	20,000 sq m AI/Photonics
Legend Biotech & J&J Expansion	Tech Lane / Obelisc	2028	15,000 sq m CAR-T Mfg
New Central Hospital (Project U)	UZ Gent	2029	133,000 sq m Clinical
UGent Chemistry Campus S11	De Sterre	2029	12,000 sq m Research

Strategic Advantage: The ARC Innovation Hub and Clinical Testing

A distinctive feature of the Ghent ecosystem is the ARC Innovation Hub, launched in 2025 at AZ Maria Middelares. This facility provides a direct "test-bed" environment, allowing HealthTech startups to validate their solutions in real-world hospital settings. This translational capability is vital for meeting the clinical evidence requirements of the MDR and the newer European Health Technology Assessment (HTA) framework, which became fully operational in 2026. By reducing the gap between prototype development and clinical adoption, Ghent facilitates a faster time-to-market for medical devices and digital tools.

The hub also benefits from the presence of UZ Gent (Ghent University Hospital), which acts as a key player for MedTech validation and clinical research. The upcoming Project U, a massive 133,000 square meter development scheduled for 2029, will further enhance the city's capacity for complex clinical trials and patient-centric innovation.

Financial and Regulatory Incentives in Flanders

The Ghent hub's potential is significantly bolstered by the Flemish government's aggressive R&D support. Flanders Innovation & Entrepreneurship (VLAIO) provides substantial grants for research and development projects, while the fiscal landscape includes an 85% innovation income deduction, effectively lowering the corporate tax rate for net innovation income.

Incentive Type	Mechanism	Target Group
Innovation Income Deduction (IID)	85% net income exemption	IP-owning firms
R&D Payroll Tax Exemption	80% withholding tax recovery	Research staff
R&D Investment Deduction	13.5% (one-time) or 20.5% (staggered)	Capital expenditures
Special Tax Status	Tax-free allowances (max 30% salary)	Inpatriate researchers
Young Innovative Company (YIC)	Full suite of tax credits	Startups under 10 years

These measures are designed to ensure that Belgium remains competitive despite the implementation of global minimum tax standards (Pillar 2). For instance, as of 2025, Belgian companies can opt to convert unused innovation income deductions into non-refundable tax credits that can be carried forward indefinitely, maintaining an effective tax rate above the 15% minimum while preserving the long-term tax advantage.

Hub 2: Porto > The Southern European Vanguard of Digital Health

Porto, Portugal, is emerging as a "growth frontier" for European HealthTech, characterised by a highly skilled workforce and a robust pipeline of university spin-outs. The city’s ecosystem value reached $7.5 Billion by late 2024, with a CAGR of 48%, a metric that significantly outperforms the global average of -14% during the same period.

Porto’s development is anchored by the University of Porto’s Science and Technology Park (UPTEC) and the ScaleUp Porto initiative, which facilitates collaboration between founders and international investors.

Workforce Dynamics and Talent Pipeline

Portugal’s MedTech workforce reached 12,800 professionals in 2024, accounting for 31% of the industry's total employment base. This sector is projected to expand at a CAGR of 6.1%, reaching 18,200 professionals by 2030. Porto specifically accounts for a significant portion of this growth, offering a competitive talent-to-cost ratio that attracts both multinational corporations and high-growth startups.

Workforce Segment	Share of Industry (%)	Primary Function
Engineering & Platform	42	Software Development / MDR Compliance
Data & AI Professionals	28	Clinical Analytics / Predictive Modeling
Cybersecurity Specialists	18	Data Privacy / NIS2 Implementation
Product & Experience	12	UX Design / Regulatory UX

Sovereign Investment and PRR Funding

The Portuguese government’s commitment to digital transformation is a primary catalyst for Porto’s potential. Under the Plano de Recuperação e Resiliência (PRR), nearly €890 million is dedicated specifically to healthcare technology and Industry 4.0 adoption. These funds are being used to modernise legacy health systems, integrate artificial intelligence into diagnostic workflows, and ensure compliance with the MDR framework.

Furthermore, the 2024 reorganisation of the National Health Service (SNS) into 39 Local Health Units (ULS) has created a unified procurement environment that favours interoperable digital solutions. Major public hospital projects are underway, including the New Hospital of the West and expansion at Trofa Saúde Maia, which serve as potential integration sites for local HealthTech innovations.

Strategic Growth Metrics for Porto (2024–2025)

The investment landscape in Porto has shown remarkable resilience. From 2024 to 2025, Porto experienced a 51% increase in total VC funding and a 163% increase in the median seed round, which now stands at $1 Million.

Metric	Value (2024/2025)	Global Benchmark Comparison
Ecosystem Value	$7.5 Billion	High Growth Tier
Median Seed Round	$1.0 Million	163% Increase YoY
Median Series A Round	$6.4 Million	Maturing Hub Status
Software Engineer Salary (Avg)	$33,000	Top 20 Affordable Talent (EU)
Total Early-Stage Funding	$129 Million	(H2 2022 – 2024)

The presence of technology centres for eight unicorns, including Revolut, Anchorage Digital, and Feedzai, underscores Porto's appeal as a hub for secure, scalable technology. The hub's focus on "Vertical AI" with robust governance is particularly relevant as investors in 2026 increasingly avoid "Black Box" models in favor of transparent, clinically validated algorithms.

Hub 3: Wroclaw > The Central European Axis of Genomic Sovereignty

Wroclaw, Poland, often referred to as the "Polish Silicon Valley," has emerged as a top-tier MedTech hub, ranking 16th globally in the sector. The city’s innovation engine is the Wroclaw Technology Park (WPT), the largest of its kind in Poland, which hosts over 200 companies and provides a specialised ecosystem for R&D, MedTech, and advanced engineering.

The primary catalyst for Wroclaw’s massive potential in the next 2 to 3 years is the formation of the Wroclaw BioTech Hub, an initiative that consolidated seven major scientific institutions in February 2025.

Genomic Infrastructure and the G4PL Project

A cornerstone of Wroclaw’s 2026–2029 outlook is the G4PL (Genomics for Poland) project. With a total value of approximately PLN 248.3 Million (approx. €57 Million), the project aims to establish a nationwide, interoperable genomic infrastructure. This infrastructure addresses a critical gap in the Polish R&D landscape by enabling high-throughput sequencing and the storage of genomic data in compliance with FAIR (Findable, Accessible, Interoperable, Reusable) principles and GDPR.

Project Aspect	G4PL Detail	Implementation Timeline
Total Project Value	PLN 248,337,770	2026 – 2029
Total External Funding	PLN 180,481,656	Phased Disbursement
Łukasiewicz – PORT Share	PLN 11,026,039	Focused on Genomic Platform
Primary Objective	Genomic Data Sovereignty	Alignment with EU 1+MG
Secondary Objective	Personalized Medicine	Precision Oncology Focus

By creating a well-characterised population dataset, Wroclaw is positioning itself as an essential partner for pan-European initiatives such as the European Excellence Hub. This "data plumbing" is expected to unlock significant value in oncology and rare disease research, areas where Wroclaw-based firms like Genomtec and Pure Biologics are already established.

Institutional Synergy: Łukasiewicz – PORT and the BioTech Hub

The Łukasiewicz Research Network – PORT (Polish Center for Technology Development) serves as the hub’s initiator and coordinator. In 2026, PORT received substantial funding for the modernisation of clean room facilities and the expansion of laser infrastructure, totalling PLN 63.2 million. These upgrades are intended to support the development of semiconductor components and micro-nanostructuring of materials, which are increasingly vital for next-generation medical sensors and intelligent surgical robotics.

The Wroclaw BioTech Hub integrates the efforts of seven major institutions:

University of Wrocław
Wrocław University of Science and Technology
Wrocław University of Environmental and Life Sciences
Wrocław Medical University
Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
Institute of Low Temperature and Structure Research, Polish Academy of Sciences
Łukasiewicz – PORT (Coordinator).

This consolidation allows Wroclaw to enter large international research consortia and lead ambitious projects that no single institution could achieve alone. The hub's focus on personalised medicine and the early detection of cancer aligns with the "Safe Hearts Plan" and other EU-wide health priorities.

VC Investment and Startup Maturation in Poland (2025–2026)

The Polish VC market in 2025 was characterized by capital concentrating in globally competitive companies. Total VC investment reached €0.8 billion across 183 transactions, with healthcare remaining the leading sector for the sixth consecutive year, accounting for 13.1% of all completed transactions.

Investment Trend	2025 Metric	Significance for Hub Growth
Total VC Flow	€797 Million	Maturing Market Foundation
Seed Stage Transactions	134 Deals	20% Increase YoY
Avg Seed Ticket Size	€1.5 Million	Stability for Risk-Taking
Healthcare Sector Share	13.1%	Continued Dominance
Biotechnology Deals	11 Rounds > €20M	Scale-up Momentum

Wroclaw's position is further strengthened by its ranking as the 16th globally in MedTech and 33rd in the Global Startup Ecosystem Index. The presence of global players such as Siemens Healthineers, combined with high-growth local startups like Biocam (capsule endoscopy) and Biotts (drug delivery), creates a balanced ecosystem of innovation and commercialisation.

Technological Convergence: The Drivers of Innovation (2027–2029)

The potential of these three hubs is underpinned by the convergence of several high-growth technological sectors. Medical devices and digital health solutions are no longer discrete categories; they are merging into interoperable ecosystems that prioritise patient-centric outcomes.

Agentic AI and Patient Twinning

Agentic AI, systems capable of autonomous decision-making and task execution, is projected to significantly impact MedTech by 2026. Approximately 30% of industry leaders identified agentic AI as an influential trend, signaling a shift from simple diagnostics to predictive, real-time clinical intervention. These systems can function as collaborators, freeing 25% to 40% of enterprise capacity and capturing incremental growth by linking discovery to commercialisation with unprecedented speed.

The application of "patient twinning", creating digital replicas of individuals to simulate treatment outcomes, is becoming a cornerstone of personalised therapy. Siemens Healthineers (Germany), with its strong presence in hubs like Wroclaw and Porto, is a leader in this space, using AI-driven imaging and analytics to transform cancer diagnostics and chronic disease management.

Robotic Surgery and Modular Ecosystems

The surgical robotics market is maturing with the entry of modular systems that challenge the historical dominance of established players. CMR Surgical (UK), with its Versius Plus platform, has targeted an installed base of over 1,000 systems by 2026, supported by a new manufacturing facility capable of producing 500 systems annually. In France, Moon Surgical is utilizing NVIDIA AI integration for its Maestro collaborative robotics system, targeting the high-growth ambulatory surgical center (ASC) market.

Ghent's Tech Lane Science Park, through its proximity to leading surgical units at UZ Gent and AZ Maria Middelares, provides the ideal environment for the testing and validation of these modular robotic systems.

The Evolution of Medical Grade Wearables

The wearable technology sector has transitioned from consumer-grade fitness tracking to medical-grade diagnostic monitoring. Oura (Finland), valued at $11 billion in late 2025, exemplifies this shift by moving into holistic health platforms that integrate with formal healthcare systems.

In Porto, Sword Health’s integration of wearable sensors with AI-driven computer vision represents the future of home-based rehabilitation and musculoskeletal care. This "AI Care" model allows clinical expertise to scale without the high headcount costs of traditional clinics, addressing the workforce crisis that currently plagues European healthcare systems.

Comparative Strategic Indicators (2026–2029)

The following table provides a high-level comparison of the strategic indicators for Ghent, Porto and Wroclaw, reflecting their developmental trajectory and potential for the next 2 to 3 years.

Hub Feature	Tech Lane Ghent (Belgium)	Porto Ecosystem (Portugal)	Wroclaw BioTech Hub (Poland)
Primary Specialisation	CAR-T / Advanced Biologics	AI-Driven Virtual Care	Genomics / MedTech R&D
Key Infrastructure	Plus Ultra / Project U	UPTEC / ScaleUp Porto	WPT / G4PL Infrastructure
Govt Funding / Incentives	VLAIO Grants / IID (85%)	PRR (€890M) / R&D Tax (12-15%)	FENG Funding / EIC Awards
VC Momentum (2025)	79% of National VC	51% Increase in VC	€0.8B Market Value
Workforce Dynamics	High-Skill Research Base	18,200 Professionals by 2030	78,000 Tech Talent Base
Clinical Validation	ARC Innovation Hub	SNS/ULS Unified Market	Wroclaw Medical Univ / PORT

Strategic Implications and Future Outlook

The evolution of Ghent, Porto, and Wroclaw as primary HealthTech and MedTech hubs suggests a broader shift in how value is created and sustained within the European Union.

The "Great Rationalisation" and Industrial Maturity

As the sector moves away from the "speculative fragmentation" of the early 2020s, the focus has shifted toward EBITDA and industrial logic. High-growth, high-burn companies are seeing their multiples compressed, while profitable platforms command premium valuations. Hubs like Porto and Wroclaw, which combine a lower cost of operation with a highly technical talent base, are uniquely positioned to foster companies that meet these new efficiency requirements.

Capitalising on the European Health Data Space (EHDS)

The implementation of the EHDS is expected to redefine the competitive "moat" for HealthTech companies. By 2029, the ability to successfully navigate the EHDS framework for secondary data use will distinguish leaders in precision medicine and AI diagnostics. Wroclaw’s investment in genomic data sovereignty and Ghent’s development of AI-specific infrastructure ("The Brain") are strategic moves intended to capture early-mover advantages in this data-centric environment.

Master the Data "Plumbing" and Interoperability

Investors in 2026 are increasingly targeting the "unsexy" backend infrastructure of healthcare—the data plumbing that enables interoperability and fluidity. This includes sovereign cloud adoption, secure EHR integration, and standardized diagnostic APIs. The development of the AWS European Sovereign Cloud for medication dispensing systems like BD’s Pyxis Pro illustrates the growing importance of data privacy and residency in the EU market.

Conclusion: The Binary Future of Compliance

The convergence of MDR, IVDR, the AI Act, and the Corporate Sustainability Reporting Directive (CSRD) in 2026 creates a binary outcome for MedTech ventures: those with certificates are investable assets; those without are distressed liabilities. Ghent, Porto, and Wroclaw have recognised this reality by building specialised support structures, from regulatory consulting at UPTEC to clinical test-beds at the ARC Innovation Hub, designed to shepherd startups through the "Regulatory Darwinism" of the current era.

By 2029, these three hubs are expected to have moved beyond the "emerging" phase into full industrial maturity. Ghent will likely be a global center for CAR-T and advanced biologic manufacturing; Porto will serve as the Southern European vanguard for AI-driven virtual care; and Wroclaw will have established itself as the Central European authority on genomic data and high-precision MedTech R&D.

For founders, investors, and pharmaceutical partners, the trajectory of these hubs represents a clear roadmap for the future of healthcare innovation in Europe.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech